Encoll
Private Company
Funding information not available
Overview
Encoll is a private, commercial-stage medical device and biomaterials company with a proprietary platform for producing ultra-pure, phosphorylated Type-I collagen. Its flagship product, Helicoll®, is an acellular dermal substitute approved for wound management and has secured an Innovative Technology contract with Vizient, Inc. The company leverages its patented Two-step enzyme Treatment Process (TTP) to serve multiple sectors, including surgical applications, biotechnology research, and skincare, positioning itself as a specialized supplier of bioactive collagen.
Technology Platform
Patented Two-step enzyme Treatment Process (TTP) for producing ultra-pure (>99%), phosphorylated Type-I bovine collagen with low immunogenicity and enhanced bioactivity.
Opportunities
Risk Factors
Competitive Landscape
Encoll competes in the biomaterials space against large, diversified medtech firms (e.g., Integra LifeSciences, Smith & Nephew) offering collagen and other wound care products, as well as other pure-play collagen companies and developers of synthetic/amniotic tissue substitutes. Its differentiation lies in its patented phosphorylation process and ultra-high purity.